Events & Insights
Cell therapy development has always demanded urgency. Programs move fast, timelines are tight, and the pressure to reach the clinic and ultimately patients is relentless. But speed alone is no longer sufficient. As more cell therapies progress through the development pipeline, regulatory expectations are rising, and the manufacturing strategies that carried programs through early-phase development must evolve to meet the demands of late-phase trials and commercialization.
Kincell Bio’s approach to late-phase process development is built around a single organizing principle: every decision, even early-phase decisions, should be made with commercial success in mind. In addition to our highly successful guiding philosophy, significant investments in expanding our Research Triangle Park (RTP) facility are further strengthening our late-phase process development capabilities.
Why Late-Phase Development Demands a Different Approach
The transition from early- to late-phase development is one of the most consequential in a cell therapy program’s lifecycle. The priorities typical of early-phase programs, such as flexibility and speed, must give way to processes that are reproducible, well-characterized, and capable of performing consistently at commercial scale. Late-phase process development at Kincell Bio focuses on exactly these demands.
Working closely with innovator clients, the Kincell team refines manufacturing processes and strengthens control strategies through structured studies and expanded analytics. These efforts must deliver reproducibility, reduce variability, and generate the process understanding required to support late-phase trials and regulatory filings, including any needed IND amendments, comparability assessments, and BLA submissions.
Analytical maturity matters just as much. Later-phase analytical development focuses on qualifying methods tied to critical quality attributes, generating the data packages regulators now require.
The Cost of Getting It Wrong
Late-phase programs with insufficiently characterized processes, immature analytical methods, or poorly defined control strategies face costly rework, and in too many cases, Complete Response Letters that delay market entry, erode investor confidence, and keep therapies from reaching patients who need them.
A recurring challenge Kincell Bio encounters is with innovators who made bespoke equipment and platform decisions under early-phase pressures, without adequately considering scalability, GMP expectations, or the cost of goods. While Kincell has helped a number of clients in this predicament, fixing these decisions late in development can be expensive, time-consuming, and avoidable.
The New MSAT/ASAT Laboratory Provides a Gateway to Commercial Readiness
As more clients move toward commercialization, Kincell invested in expanding its RTP facility, its center of excellence for pivotal supply, commercialization, and commercial manufacturing. A strategic part of the RTP expansion is a dedicated 1,200 ft2 MSAT/ASAT laboratory, purpose-built to support clients as they advance toward commercialization.
The lab sits at the intersection of process development and commercial manufacturing, serving as a key resource for late-stage process characterization, technology transfer, process validation, and analytical method qualification. For clients preparing to file a BLA, this dedicated lab and its experts will provide essential support.
The lab is well-equipped with cell selection equipment, including CliniMACS Prodigy® and CliniMACS Plus®, G-Rex® for cell expansion, CTS™ Xenon™ and ExPERT GTx™ for electroporation, and Sepax™ C-Pro, CTS™ Rotea™, and Fresenius Kabi LOVO® for cell washing and formulation. Analytical capabilities include flow cytometry, dPCR, and a multimode plate reader, along with a metabolite and dissolved-gas analyzer and a controlled-rate freezer. The lab is also outfitted with comprehensive temperature-controlled environment options, including ambient, 2-8°C, -80°C, and liquid nitrogen conditions.
Enhancing Our Two-Site Strategy
The new MSAT/ASAT laboratory is a deliberate addition to Kincell Bio’s two-site model. Gainesville, Florida, is an early-phase focused facility where programs are onboarded, processes are developed, and clinical manufacturing begins.
As programs mature and progress through development, the MSAT/ASAT lab ensures the back half of that journey is as well-resourced as the front end, reducing risk from late-stage development through to commercial launch.
For cell therapy programs on the path to commercialization, the margin for error is narrow, and the expectations are high. Kincell Bio’s late-phase process development capabilities, anchored by the new MSAT/ASAT laboratory, are designed to support successful market entry. Contact us to learn how the Kincell team can help you.
